Miragen Therapeutics, Inc. (MGEN) Insider Adam Scott Levy Buys 9,090 Shares

Miragen Therapeutics, Inc. (NASDAQ:MGEN) insider Adam Scott Levy bought 9,090 shares of the stock in a transaction that occurred on Tuesday, February 13th. The shares were purchased at an average cost of $5.50 per share, with a total value of $49,995.00. Following the purchase, the insider now directly owns 10,540 shares of the company’s stock, valued at $57,970. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Shares of Miragen Therapeutics, Inc. (NASDAQ:MGEN) remained flat at $$5.50 during midday trading on Tuesday. The company’s stock had a trading volume of 236,096 shares, compared to its average volume of 308,205. Miragen Therapeutics, Inc. has a 52-week low of $5.01 and a 52-week high of $18.00. The firm has a market cap of $122.70, a P/E ratio of 36.67 and a beta of 1.43. The company has a quick ratio of 7.11, a current ratio of 7.11 and a debt-to-equity ratio of 0.04.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. BSW Wealth Partners bought a new stake in Miragen Therapeutics in the third quarter valued at $203,000. Russell Investments Group Ltd. bought a new stake in Miragen Therapeutics in the third quarter valued at $147,000. SG Americas Securities LLC bought a new stake in Miragen Therapeutics in the third quarter valued at $250,000. Seaward Management Limited Partnership bought a new stake in Miragen Therapeutics in the third quarter valued at $117,000. Finally, Aveo Capital Partners LLC bought a new stake in Miragen Therapeutics in the fourth quarter valued at $279,000. 22.59% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts recently weighed in on the stock. Oppenheimer assumed coverage on shares of Miragen Therapeutics in a research note on Friday, January 12th. They set an “outperform” rating and a $13.00 target price for the company. B. Riley assumed coverage on shares of Miragen Therapeutics in a research note on Friday, January 5th. They set a “buy” rating and a $15.50 target price for the company. Chardan Capital reissued a “buy” rating on shares of Miragen Therapeutics in a research note on Tuesday, January 16th. Zacks Investment Research raised shares of Miragen Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 target price for the company in a research note on Thursday, October 19th. Finally, Cann assumed coverage on shares of Miragen Therapeutics in a research note on Friday, January 12th. They set an “outperform” rating and a $13.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $16.46.

COPYRIGHT VIOLATION NOTICE: “Miragen Therapeutics, Inc. (MGEN) Insider Adam Scott Levy Buys 9,090 Shares” was published by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/02/13/miragen-therapeutics-inc-mgen-insider-adam-scott-levy-buys-9090-shares.html.

Miragen Therapeutics Company Profile

Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.

Insider Buying and Selling by Quarter for Miragen Therapeutics (NASDAQ:MGEN)

Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply